Latest News

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare...

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conf

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic G...

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Trea...

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Reve...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue O

Teva Releases Q2 2025 Aide Memoire

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 3...

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 20

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (frema...

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezum

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-...

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total...

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maxi

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Sett...

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperi...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone)

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovat...

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation a

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA